QQQ na na (na)
DIA na na (na)
SPY na na (na)
TLT na na (na)
GLD na na (na)
$ na
-- x --
-- x --
-- - --
na - na
0
na
na
na
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-25-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $2.5 price ...

 hc-wainwright--co-maintains-buy-on-unicycive-therapeutics-lowers-price-target-to-25

HC Wainwright & Co. analyst Ed Arce maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price targe...

 unicycive-secures-patent-for-kidney-disease-treatment-uni-494-valid-until-2040

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-therapeutics-inc-files-for-resale-of-up-to-50m-shares-by-the-selling-stockholders

- SEC Filing

 unicycive-therapeutics-joins-russell-microcap-index

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-showcases-data-on-kidney-disease-therapies-at-european-renal-congress

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Associ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION